1 / 4

Hepatitis Vaccine Market Set for Rapid Growth and Trend, by 2026

Hepatitis is one of the most prevalent infectious disease across the globe, it attracted attention from health bodies such as World Health Organization (WHO) due to its severity. Increasing incidence of hepatitis worldwide is estimated to drive growth of the Hepatitis Vaccine Market.

ravikiran12
Download Presentation

Hepatitis Vaccine Market Set for Rapid Growth and Trend, by 2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hepatitis Vaccine Market Infrastructure Growth and Development in US by 2026 Hepatitis Vaccine Market, by Indication (Hepatitis A and Hepatitis B), By Vaccine Type (Recombinant Vaccine and Inactivated Vaccine) by Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies) and by Geography - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026 Hepatitis is an infectious disease caused due to hepatitis virus type A, B, and C, which leads to liver associated disease such as Hepatitis A, hepatitis B, hepatitis C, liver cirrhosis, hepatocellular carcinoma, and liver failure. It may lead to death of infected person. The infection is spread due to transmission of hepatitis A and hepatitis B virus due contact with body fluids (blood etc.) of infected person. Hepatitis vaccine are available for prevention of both hepatitis A and hepatitis B which prevents its occurrence by boosting immunity of the person thereby avoiding complications such as liver failure and cancer. Infection is most prevalent in children. Globally hepatitis B is more prevalent than hepatitis A. Market Dynamics Hepatitis is one of the most prevalent infectious disease across the globe, it attracted attention from health bodies such as World Health Organization (WHO) due to its severity. Increasing incidence of hepatitis worldwide is estimated to drive growth of the H epatitis Hepatitis Report published in 2017 by WHO, an estimated 325 million people worldwide are living V accine M arket. According to World

  2. with chronic hepatitis B virus infection (HBV) or hepatitis C virus (HCV) infection. Moreover, an estimated 1.34 million deaths in 2015, were caused due to viral hepatitis. Around 1.75 million people were infected with hepatitis B virus infection (HCV) in 2015. Increasing global population (live births) is another factor driving growth of the hepatitis vaccine market. As per statistics given by the World Population Report published in 2017, world population would surpass mark of 9 billion by 2025 thereby adding more live birth each year. According to guideline published by WHO, vaccine for hepatitis B has to administer within first 24 hour of the birth in order to prevent the hepatitis B infection to infant. Furthermore, increased awareness amongst masses about benefits of hepatitis vaccination would further aid in market growth for the hepatitis vaccine market. There is attractive opportunity to introduce hepatitis C vaccine as it is one of most prevalent type of hepatitis after hepatitis B and has no vaccine available for it. Also, currently available vaccine for hepatitis B are ineffective in many adults along with those suffering from diabetes. In these cases person do not develop adequate immunity even after two or three shots of vaccine. Therefore, new improved vaccine could prove beneficial and propel growth of the market. Competitive Analysis Key players present in the hepatitis vaccines market are Merck and Company, GlaxoSmithKline, Sanofi Pasture, CSL Behring GmbH, Novartis AG and Pfizer Inc. Few leading brands in hepatitis vaccine market are Engerix-B, Havrix (Glaxosmithkline), Recombivax, Vaqta (Merck and Company), Euvax – Avaxim (Sanofi Pasteur), and Shanvac B (Shantha Biotech) Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1537 Amongst indication, hepatitis B vaccine holds larger market share due to higher prevalence of hepatitis B infection and presence of different companies in the production and marketing of these vaccine. Recombinant vaccine is largest shareholder in vaccine type segment as it is most commonly used in the hepatitis B vaccine. Amongst distribution channel retail pharmacy holds major share.

  3. Market Taxonomy On the basis of Indication •Hepatitis A •Hepatitis B On the basis of Vaccine Type •Recombinant Vaccine •Inactivated Vaccine On the basis of Distribution Channel •Hospitals •Retail Pharmacy •Online Pharmacy Regional Dynamics On the basis of regions, hepatitis vaccine market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to dominate the hepatitis vaccine market, owing to high healthcare spending and availability of robust healthcare infrastructure in the region. According to Centre for Disease Control (CDC) data in 2016, the U.S. had 0.6 cases per 1, 00,000 population. Even though this rate of incidence is low as compared to regions such as Asia Pacific and Africa, still due to highest healthcare spending by U.S. population hepatitis vaccine North America is lucrative market for hepatitis vaccine market. Asia Pacific has greatest burden of hepatitis (154 million people with hepatitis B) currently as mentioned in World Hepatitis Report, 2017 and it is attractive market for hepatitis market due to the larger population getting infected from the hepatitis. According to the WHO, it is estimated that 2% to 5% of general population is affected chronically in Asia Pacific. Prevalence of hepatitis B is the highest in Middle East & Africa where adult population is chronically infected.

  4. About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1–206–701–6702 Email: sales@coherentmarketinsights.com

More Related